Your browser doesn't support javascript.
Pharmacological treatments of COVID-19.
Sahebnasagh, Adeleh; Avan, Razieh; Saghafi, Fatemeh; Mojtahedzadeh, Mojataba; Sadremomtaz, Afsaneh; Arasteh, Omid; Tanzifi, Asal; Faramarzi, Fatemeh; Negarandeh, Reza; Safdari, Mohammadreza; Khataminia, Masoud; Rezai Ghaleno, Hassan; Habtemariam, Solomon; Khoshi, Amirhosein.
  • Sahebnasagh A; Clinical Research Center, Department of Internal Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Avan R; Department of Clinical Pharmacy, Medical Toxicology and Drug Abuse Research Center (MTDRC), Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran.
  • Saghafi F; Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Mojtahedzadeh M; Department of Clinical Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Sadremomtaz A; XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, 9700 AD, Groningen, The Netherlands.
  • Arasteh O; Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Tanzifi A; Sepanta Faragene Azma Research Laboratory. Co. LTD., Gorgan, Iran.
  • Faramarzi F; Department of Parasitology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Negarandeh R; Clinical Pharmacy Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Safdari M; Student Research Committee, Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
  • Khataminia M; Department of Orthopedic Surgery, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran.
  • Rezai Ghaleno H; Student Research Committee, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Habtemariam S; Department of Surgery, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
  • Khoshi A; Pharmacognosy Research Laboratories and Herbal Analysis Services, University of Greenwich, Central Avenue, Chatham-Maritime, Kent, ME4 4TB, UK.
Pharmacol Rep ; 72(6): 1446-1478, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-2060162
ABSTRACT
The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal: Pharmacol Rep Journal subject: Pharmacology Year: 2020 Document Type: Article Affiliation country: S43440-020-00152-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study / Randomized controlled trials Limits: Animals / Humans Language: English Journal: Pharmacol Rep Journal subject: Pharmacology Year: 2020 Document Type: Article Affiliation country: S43440-020-00152-9